Educational needs of hematologists and laboratory professionals regarding factor activity assays

Figures & data

Table 1 Hematologist practice characteristics.

Characteristic	Percentage of total hematologists (N=51)	Percentage of HTC-affiliated hematologists (n=12)	Percentage of non-HTC-affiliated hematologists (n=39)
Years in practice
1–5	13	0	18
6–10	20	25	18
11–20	43	58	38
21–30	18	17	18
>30	6	0	8
Number of patients seen each week
≤1	23	8	28
2–10	47	8	59
11–20	12	34	5
21–30	4	8	3
>30	14	42	5
Number of factor assays ordered each month
≤1	16	0	21
2–10	32	8	39
11–20	22	33	18
21–30	22	33	18
>30	8	25	3

Abbreviation: HTC, hemophilia treatment center.

Figure 1 Hematologists’ circumstances for ordering factor activity testing.

Notes: Participants selected all options that applied. ^aOther was specified as change in bleeding phenotype. ^bOther was specified as central nervous system bleeding.
Abbreviation: HTC, hemophilia treatment center.

Figure 2 Hematologists’ general familiarity with coagulation assays and laboratories.

Abbreviation: HTC, hemophilia treatment center.

Figure 3 Hematologists’ perceptions regarding chromogenic assays (A) and concerns regarding OS assays (B).

Abbreviations: CS, chromogenic substrate; HTC, hemophilia treatment center; OS, one stage.

Table 2 Laboratory professional characteristics

Characteristic	Percentage of laboratory professionals (N=57)
Professional title
Director	35
Manager	28
Supervisor/coordinator	14
Technician/scientist	9
Administrator	5
Others	7
Number of years in current position
≤4	32
5–9	25
10–14	19
≥15	25
Organization type
Hospital	88
Independent laboratory	11
Government laboratory	2
HTC affiliation
Affiliated	18
Not affiliated	77
Not sure	5
Number of FVIII assays directly performed annually
0	39
1–20	25
21–100	16
101–500	10
>500	10
Number of FIX assays directly performed annually
0	49
1–20	35
21–100	4
101–500	8
>500	4
Assay use for diagnosis and monitoring to measure FVIII
One-stage assay	72
Chromogenic assay	10
Both one-stage and chromogenic assays	17

Abbreviations: FVIII, factor VIII; FIX, factor IX; HTC, hemophilia treatment center.

Figure 4 Laboratory professionals’ perceptions regarding chromogenic assays (A), concerns regarding OS assays (B), and perceived barriers to chromogenic assay use (C).

Abbreviations: CS, chromogenic substrate; FDA, US Food and Drug Administration; OS, one stage; QC, quality control.

Figure 5 Laboratory professionals’ preferred formats for receiving medical education.